Experts report toxicity reduction in polymeric prodrug pre-clinical trials

Preclinical studies have shown that a newly developed polymeric prodrug when administered subcutaneously (SC), reduces the production of hemotoxic metabolites in the liver and the risk of hemolytic anemia, thereby potentially modifying the therapeutic index of Tafenoquine (TQ).